Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.
ApoE Kyoto (p.R43C)
ApoE Sendai (p.R163P)
Atherosclerosis
Lipoprotein glomerulopathy
Recombinant adenovirus
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
04 03 2021
04 03 2021
Historique:
received:
01
10
2020
accepted:
22
02
2021
entrez:
5
3
2021
pubmed:
6
3
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Lipoprotein glomerulopathy (LPG) is a rare autosomal dominant kidney disease that is most commonly caused by mutations in ApoE Kyoto (p.R43C) and ApoE Sendai (p.R163P). Differences in phenotype among the various ApoE mutations have been suggested, but the pathogenic role of ApoE Kyoto has not been validated in an animal model. This study intended to establish an ApoE Kyoto murine model and to further compare the pathologic differences between ApoE Kyoto and ApoE Sendai. Male ApoE-deficient mice, 3 months of age, were divided into five groups, including the AD-ApoE Sendai, AD-ApoE Kyoto, AD-ApoE3, AD-eGFP, and ApoE (-/-) groups. The first four groups received recombinant adenovirus that contained the entire coding regions of the human ApoE Sendai and ApoE Kyoto, apoE3, and eGFP genes, respectively. Fasting blood and urine samples were collected at multiple time points. Lipid profiles and urine albumin-creatinine ratio were measured. Renal and aortic histopathologic alterations were analyzed. After virus injection, plasma human ApoE was detected and rapidly reached the maximum level at 4-6 days in the AD-ApoE Kyoto and AD-ApoE Sendai groups (17.4 ± 3.1 µg/mL vs.: 22.2 ± 4.5 µg/mL, respectively) and at 2 days in the AD-ApoE3 group (38.4 µg/mL). The serum total cholesterol decreased by 63%, 65%, and 73% in the AD-ApoE Kyoto, AD-ApoE Sendai and AD-ApoE3 groups, respectively. There were no significant changes in serum triglyceride and urinary albumin-creatinine ratio among the five groups. Typical lipoprotein thrombi with positive ApoE staining were detected in the AD-ApoE Kyoto and AD-ApoE Sendai groups. The Oil-red O-positive glomerular area tended to be higher in the AD-ApoE Kyoto group (9.2%) than in the AD-ApoE Sendai (3.9%), AD-ApoE3 (4.8%), AD-eGFP (2.9%), and ApoE (-/-) (3.6%) groups. The atherosclerotic plaque area in the aorta was lower in the group injected with various ApoE mutations than in the group without injection of ApoE mutation. In this animal study, we first established an ApoE Kyoto mutation murine model and confirmed its pathogenic role in LPG. Our results suggested that LPG may be more severe with the ApoE Kyoto than with the ApoE Sendai.
Sections du résumé
BACKGROUND
Lipoprotein glomerulopathy (LPG) is a rare autosomal dominant kidney disease that is most commonly caused by mutations in ApoE Kyoto (p.R43C) and ApoE Sendai (p.R163P). Differences in phenotype among the various ApoE mutations have been suggested, but the pathogenic role of ApoE Kyoto has not been validated in an animal model. This study intended to establish an ApoE Kyoto murine model and to further compare the pathologic differences between ApoE Kyoto and ApoE Sendai.
METHOD
Male ApoE-deficient mice, 3 months of age, were divided into five groups, including the AD-ApoE Sendai, AD-ApoE Kyoto, AD-ApoE3, AD-eGFP, and ApoE (-/-) groups. The first four groups received recombinant adenovirus that contained the entire coding regions of the human ApoE Sendai and ApoE Kyoto, apoE3, and eGFP genes, respectively. Fasting blood and urine samples were collected at multiple time points. Lipid profiles and urine albumin-creatinine ratio were measured. Renal and aortic histopathologic alterations were analyzed.
RESULTS
After virus injection, plasma human ApoE was detected and rapidly reached the maximum level at 4-6 days in the AD-ApoE Kyoto and AD-ApoE Sendai groups (17.4 ± 3.1 µg/mL vs.: 22.2 ± 4.5 µg/mL, respectively) and at 2 days in the AD-ApoE3 group (38.4 µg/mL). The serum total cholesterol decreased by 63%, 65%, and 73% in the AD-ApoE Kyoto, AD-ApoE Sendai and AD-ApoE3 groups, respectively. There were no significant changes in serum triglyceride and urinary albumin-creatinine ratio among the five groups. Typical lipoprotein thrombi with positive ApoE staining were detected in the AD-ApoE Kyoto and AD-ApoE Sendai groups. The Oil-red O-positive glomerular area tended to be higher in the AD-ApoE Kyoto group (9.2%) than in the AD-ApoE Sendai (3.9%), AD-ApoE3 (4.8%), AD-eGFP (2.9%), and ApoE (-/-) (3.6%) groups. The atherosclerotic plaque area in the aorta was lower in the group injected with various ApoE mutations than in the group without injection of ApoE mutation.
CONCLUSIONS
In this animal study, we first established an ApoE Kyoto mutation murine model and confirmed its pathogenic role in LPG. Our results suggested that LPG may be more severe with the ApoE Kyoto than with the ApoE Sendai.
Identifiants
pubmed: 33663537
doi: 10.1186/s12967-021-02765-x
pii: 10.1186/s12967-021-02765-x
pmc: PMC7934380
doi:
Substances chimiques
Apolipoproteins E
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
97Références
J Am Soc Nephrol. 2002 Jun;13(6):1527-33
pubmed: 12039982
Kidney Int. 2020 Feb;97(2):279-288
pubmed: 31874799
J Atheroscler Thromb. 2011;18(6):531-5
pubmed: 21325775
Atherosclerosis. 2009 May;204(1):121-6
pubmed: 18930458
Nephrol Dial Transplant. 2012 Oct;27(10):3899-907
pubmed: 22863838
Kidney Int. 1999 Aug;56(2):421-7
pubmed: 10432380
J Biol Chem. 1982 Apr 25;257(8):4171-8
pubmed: 7068630
Mol Genet Genomic Med. 2020 Aug;8(8):e1281
pubmed: 32441489
Clin Exp Nephrol. 2014 Apr;18(2):220-4
pubmed: 24570178
J Lipid Res. 2013 Jan;54(1):164-76
pubmed: 23110818
J Lipid Res. 2018 Dec;59(12):2339-2348
pubmed: 30309894
J Atheroscler Thromb. 2011;18(6):542-3
pubmed: 21670560
Clin Exp Nephrol. 2014 Apr;18(2):214-7
pubmed: 24149835
Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1852-7
pubmed: 16763161
J Am Soc Nephrol. 1997 May;8(5):820-3
pubmed: 9176854
Kidney Int. 2014 Feb;85(2):416-24
pubmed: 24025644
J Biol Chem. 2000 Oct 6;275(40):31269-73
pubmed: 10903326
Metabolism. 2002 Feb;51(2):201-5
pubmed: 11833049
J Lipid Res. 2014 Oct;55(10):2073-81
pubmed: 25183802
J Atheroscler Thromb. 2018 Aug 1;25(8):733-740
pubmed: 29398675
J Atheroscler Thromb. 2011;18(6):536-41
pubmed: 21467726